Non-infectious complications after hematopoietic cell transplantation
DOI:
https://doi.org/10.46765/2675-374X.2025v6n1e283Keywords:
Hematopoietic Stem Cell Transplantation, Complications, Pediatric PatientsAbstract
Hematopoietic cell transplantation (HCT) is a curative treatment for children with malignant and non-malignant diseases. In recent years, we have observed a significant increase in the survival of these patients, due to improved resources. In this article, we discuss non-infectious complications related to HCT, including their management, prevention, and best options of treatment.
References
1. Pediatric Transplant Working Group. Consensus guidelines for pediatric hematopoietic stem cell transplantation from Brazilian Society for Blood and Marrow Transplantation and Cellular Therapy. 7ª ed. Journal of Bone Marrow Transplantation and Cellular Therapy; 2021.
2. Sureda A, Corbacioglu S, Greco R, Kroger N, Carreras E. The EBMT handbook: haematopoietic cell transplantation and cellular therapies. Europe: EBMT; 2024. DOI: https://doi.org/10.1007/978-3-031-44080-9
3. Cabanillas Stanchi KM, Vek J, Schlegel P, Rupprecht JV, Flaadt T, Weber S, Michaelis S, Lang P, Handgretinger R, Döring M. Antiemetic prophylaxis with fosaprepitant and granisetron in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation. J Cancer Res Clin Oncol. 2020;146(4):1089–100. https://doi.org/10.1007/s00432-020-03143-8 DOI: https://doi.org/10.1007/s00432-020-03143-8
4. Cabanillas Stanchi KM, Willier S, Vek J, Schlegel P, Queudeville M, Rieflin N, Klaus V, Gansel M, Rupprecht JV, Flaadt T, Binder V, Feuchtinger T, Lang P, Handgretinger R, Döring M. Antiemetic prophylaxis with fosaprepitant and 5-HT3-receptor antagonists in pediatric patients undergoing autologous hematopoietic stem cell transplantation. Drug Des Devel Ther. 2020;14:3915-27. https://doi.org/10.2147/DDDT.S260887 DOI: https://doi.org/10.2147/DDDT.S260887
5. Hesketh PJ, Kris MG, Basch E, Bohlke K, Barbour SY, Clark-Snow RA, Danso MA, Dennis K, Dupuis LL, Dusetzina SB, Eng C, Feyer PC, Jordan K, Noonan K, Sparacio D, Lyman GH. Antiemetics: ASCO Guideline Update. J Clin Oncol. 2020;38(24):2782–97. https://doi.org/10.1200/JCO.20.01296 DOI: https://doi.org/10.1200/JCO.20.01296
6. Paw Cho Sing E, Tomlinson GA, Schechter T, Ali M, Phelan R, Rassekh SR, McKinnon K, Bier GA, van de Wetering M, Gomez S, Sung L, Dupuis LL. Impact of dexamethasone on transplant-related mortality in pediatric patients: a multi-site, propensity score-weighted, retrospective assessment. Support Care Cancer. 2024;32(8):552. https://doi.org/10.1007/s00520-024-08732-8 DOI: https://doi.org/10.1007/s00520-024-08732-8
7. Flank J, Sparavalo J, Vol H, Hagen L, Stuhler R, Chong D, Courtney S, Doyle JJ, Gassas A, Schechter T, Dupuis LL. The burden of chemotherapy-induced nausea and vomiting in children receiving hematopoietic stem cell transplantation conditioning: a prospective study. Bone Marrow Transplant. 2017;52(9):1294–9. https://doi.org/10.1038/bmt.2017.112 DOI: https://doi.org/10.1038/bmt.2017.112
8. Kusnierczyk NM, Saunders EF, Dupuis LL. Outcomes of antiemetic prophylaxis in children undergoing bone marrow transplantation. Bone Marrow Transplant. 2002;30(2):119–24. https://doi.org/10.1038/sj.bmt.1703579 DOI: https://doi.org/10.1038/sj.bmt.1703579
9. Nahata MC, Hui LN, Koepke J. Efficacy and safety of ondansetron in pediatric patients undergoing bone marrow transplantation. Clin Ther. 1996;18(3):466–76. https://doi.org/10.1016/s0149-2918(96)80027-0 DOI: https://doi.org/10.1016/S0149-2918(96)80027-0
10. Sonis ST, Elting LS, Keefe D, Peterson DE, Schubert M, Hauer-Jensen M, Bekele BN, Raber-Durlacher J, Donnelly JP, Rubenstein EB; Mucositis Study Section of the Multinational Association for Supportive Care in Cancer; International Society for Oral Oncology. Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer. 2004;100(9 Suppl.):1995–2025. https://doi.org/10.1002/cncr.20162 DOI: https://doi.org/10.1002/cncr.20162
11. Niscola P. Mucositis in malignant hematology. Expert Rev Hematol. 2010;3(1):57–65. https://doi.org/10.1586/ehm.09.71 DOI: https://doi.org/10.1586/ehm.09.71
12. Cheng KK, Molassiotis A, Chang AM, Wai WC, Cheung SS. Evaluation of an oral care protocol intervention in the prevention of chemotherapy-induced oral mucositis in pediatric cancer patients. Eur J Cancer. 2001;37(16):2056–63. https://doi.org/10.1016/s0959-8049(01)00098-3 DOI: https://doi.org/10.1016/S0959-8049(01)00098-3
13. Rubenstein EB, Peterson DE, Schubert M, Keefe D, McGuire D, Epstein J, Elting LS, Fox PC, Cooksley C, Sonis ST; Mucositis Study Section of the Multinational Association for Supportive Care in Cancer; International Society for Oral Oncology. Clinical practice guidelines for the prevention and treatment of cancer therapy induced oral and gastrointestinal mucositis. Cancer. 2004;100(9 Suppl.):2026–46. https://doi.org/10.1002/cncr.20163 DOI: https://doi.org/10.1002/cncr.20163
14. Genot MT, Klastersky J. Low-level laser for prevention and therapy of oral mucositis induced by chemotherapy or radiotherapy. Curr Opin Oncol. 2005;17(3):236–40. https://doi.org/10.1097/01.cco.0000156196.22249.76 DOI: https://doi.org/10.1097/01.cco.0000156196.22249.76
15. Blijlevens NM, Sonis ST. Palifermin: a keratinocyte growth factor with multiple biologic activities in preventing chemotherapy- and radiotherapy-induced mucositis. Ann Oncol. 2007;18(5):818–26. https://doi.org/10.1093/annonc/mdl332 DOI: https://doi.org/10.1093/annonc/mdl332
16. Papas AS, Clark RE, Martuscelli G, O’Loughlin KT, Johansen E, Miller KB. A prospective, randomized trial for the prevention of mucositis in patients undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant. 2003;31(8):705–12. https://doi.org/10.1038/sj.bmt.1703870 DOI: https://doi.org/10.1038/sj.bmt.1703870
17. MacMillan ML, DeFor TE, Young JA, Dusenbery KE, Blazar BR, Slungaard A, Zierhut H, Weisdorf DJ, Wagner JE. Alternative donor hematopoietic cell transplantation for Fanconi anemia. Blood. 2015;125(24):3798–804. https://doi.org/10.1182/blood-2015-02-626002 DOI: https://doi.org/10.1182/blood-2015-02-626002
18. Gluckman E, Lotsberg J, Devergie A, Zhao XM, Melo R, Gomez-Morales M, Nebout T, Mazeron MC, Perol Y. Prophylaxis of herpes infections after bone-marrow transplantation by oral acyclovir. Lancet. 1983;2(8352):706–8. https://doi.org/10.1016/s0140-6736(83)92248-1 DOI: https://doi.org/10.1016/S0140-6736(83)92248-1
19. Droller MJ, Saral R, Santos G. Prevention of cyclophosphamide-induced hemorrhagic cystitis. Urology. 1982;20(3):256–8. https://doi.org/10.1016/0090-4295(82)90633-1 DOI: https://doi.org/10.1016/0090-4295(82)90633-1
20. Hirsch HH, Pergam SA. Human adenovirus, polyomavirus, and parvovirus infections in patients undergoing hematopoietic stem-cell transplantation. In: Forman SJ, Nagrin RS, Antin H, Appelbaum FR, editors. Thomas’ hematopoietic cell transplantation. 5ª ed. Hoboken: Wiley; 2016. p. 1090–104. DOI: https://doi.org/10.1002/9781118416426.ch93
21. Lia G, Giaccone L, Leone S, Bruno B. Biomarkers for early complications of endothelial origin after allogeneic hematopoietic stem cell transplantation: do they have a potential clinical role? Front Immunol. 2021;12:641427. https://doi.org/10.3389/fimmu.2021.641427 DOI: https://doi.org/10.3389/fimmu.2021.641427
22. Hingorani S. Renal complications after hematopoietic stem cell transplantation. N Engl J Med. 2016;374(23):2256–67. https://doi.org/10.1056/nejmra1404711 DOI: https://doi.org/10.1056/NEJMra1404711
23. Ganguly N, Clough LA, Dubois LK, Mcguirk JP, Abhyankar S, Aljitawi OS, O’Neal N, Divine CL, Ganguly S. Low-dose cidofovir in the treatment of symptomatic BK virus infection in patients undergoing allogeneic hematopoietic stem cell transplantation: a retrospective analysis of an algorithmic approach. Transpl Infect Dis. 2010;12(5):406–11. https://doi.org/10.1111/j.1399-3062.2010.00513.x DOI: https://doi.org/10.1111/j.1399-3062.2010.00513.x
24. Bridges B, Donegan S, Badros A. Cidofovir bladder instillation for the treatment of BK hemorrhagic cystitis after allogeneic stem cell transplantation. Am J Hematol. 2006;81(7):535–7. https://doi.org/10.1002/ajh.20567 DOI: https://doi.org/10.1002/ajh.20567
25. Tirindelli MC, Flammia GP, Bove P, Cerretti R, Cudillo L, De Angelis G, Picardi A, Annibali O, Nobile C, Cerchiara E, Dentamaro T, De Fabritiis P, Lanti A, Ferraro AS, Sergi F, Di Piazza F, Avvisati G, Arcese W; Rome Transplant Network. Fibrin glue therapy for severe hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2014;10(10):1612–7. https://doi.org/10.1016/j.bbmt.2014.06.018 DOI: https://doi.org/10.1016/j.bbmt.2014.06.018
26. Dvorak CC, Higham C, Shimano KA. Transplant-associated thrombotic microangiopathy in pediatric hematopoietic cell transplant recipients: a practical approach to diagnosis and management. Front Pediatr. 2019;7:133. https://doi.org/10.3389/fped.2019.00133 DOI: https://doi.org/10.3389/fped.2019.00133
27. Lazana I. Transplant-associated thrombotic microangiopathy in the context of allogenic hematopoietic stem cell transplantation: where we stand. Int J Mol Sci. 2023;24(2):1159. https://doi.org/10.3390/ijms24021159 DOI: https://doi.org/10.3390/ijms24021159
28. Schoettler ML, Carreras E, Cho B, Dandoy CE, Ho VT, Jodele S, Moissev I, Sanchez-Ortega I, Srivastava A, Atsuta Y, Carpenter P, Koreth J, Kroger N, Ljungman P, Page K, Popat U, Shaw BE, Sureda A, Soiffer R, Vasu S. Harmonizing definitions for diagnostic criteria and prognostic assessment of transplantation associated thrombotic microangiopathy: a report on behalf of the European Society for Blood and Marrow Transplantation, American Society for Transplantation and Cellular Therapy, Asia-Pacific Blood and Marrow Transplantation Group, and Center for International Blood and Marrow Transplant Research. Transplant Cell Ther. 2022;29(3):151–63. https://doi.org/10.1016/j.jtct.2022.11.015 DOI: https://doi.org/10.1016/j.jtct.2022.11.015
29. Mizuno K, Dandoy CE, Teusink-Cross A, Davies SM, Vinks AA, Jodele S. Eculizumab precision-dosing algorithm for thrombotic microangiopathy in children and young adults undergoing HSCT. Blood Adv. 2022;6(5):1454–63. https://doi.org/10.1182/bloodadvances.2021006523 DOI: https://doi.org/10.1182/bloodadvances.2021006523
30. Ardissino G, Capone V, Tedeschi S, Porcaro L, Cugno M. Complement system as a new target for hematopoietic stem cell transplantation-related thrombotic microangiopathy. Pharmaceuticals. 2022;15(7):845. https://doi.org/10.3390/ph15070845 DOI: https://doi.org/10.3390/ph15070845
31. Consonni F, Ciulli A, Cuzzubbo D, Frenos S, Sanvito MC, Tondo A, Tintori V, Gambineri E. Refractory thrombocytopenia is the earliest diagnostic criterion for sinusoidal obstruction syndrome in children. J Pediatr Hematol Oncol. 2024;46(7):e501–7. https://doi.org/10.1097/mph.0000000000002938 DOI: https://doi.org/10.1097/MPH.0000000000002938
32. Northup PG, Garcia-Pagan JC, Garcia-Tsao G, Intagliata NM, Superina RA, Roberts LN, Lisman T, Valla DC. Vascular liver disorders, portal vein thrombosis, and procedural bleeding in patients with liver disease: 2020 practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 2021;73(1):366–413. https://doi.org/10.1002/hep.31646 DOI: https://doi.org/10.1002/hep.31646
33. Vion AC, Rautou PE, Durand F, Boulanger CM, Valla DC. Interplay of inflammation and endothelial dysfunction in bone marrow transplantation: focus on hepatic veno-occlusive disease. Semin Thromb Hemost. 2015;41(6):629–43. https://doi.org/10.1055/s-0035-1556728 DOI: https://doi.org/10.1055/s-0035-1556728
34. Sousa-Pimenta M, Martins Â, Estevinho LM, Pinho Vaz C, Leite L, Mariz J. Hepatic sinusoidal obstruction syndrome/veno-occlusive disease (SOS/VOD) primary prophylaxis in patients undergoing hematopoietic stem cell transplantation: a network meta-analysis of randomized controlled trials. J Clin Med. 2024;13(22):6917. https://doi.org/10.3390/jcm13226917 DOI: https://doi.org/10.3390/jcm13226917
35. Kammersgaard MB, Kielsen K, Heilmann C, Ifversen M, Müller K. Assessment of the proposed EBMT pediatric criteria for diagnosis and severity grading of sinusoidal obstruction syndrome. Bone Marrow Transplant. 2019;54(9):1406–18. https://doi.org/10.1038/s41409-018-0426-8 DOI: https://doi.org/10.1038/s41409-018-0426-8
36. Mahadeo KM, Bajwa R, Abdel-Azim H, Lehmann LE, Duncan C, Zantek N, Vittorio J, Angelo J, McArthur J, Schadler K, Chan S, Tewari P, Khazal S, Auletta JJ, Choi SW, Shoberu B, Kalwak K, Harden A, Kebriaei P, Abe JI, Li S, Moffet JR, Abraham S, Tambaro FP, Kleinschmidt K, Richardson PG, Corbacioglu S; Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) Network and the Pediatric Diseases Working Party of the European Society for Blood and Marrow Transplantation. Diagnosis, grading, and treatment recommendations for children, adolescents, and young adults with sinusoidal obstructive syndrome: an international expert position statement. Lancet Haematol. 2020;7(1):e61–e72. https://doi.org/10.1016/S2352-3026(19)30201-7 DOI: https://doi.org/10.1016/S2352-3026(19)30201-7
37. Bajwa RPS, Mahadeo KM, Taragin BH, Dvorak CC, McArthur J, Jeyapalan A, Duncan CN, Tamburro R, Gehred A, Lehmann L, Richardson P, Auletta JJ, Woolfrey AE. Consensus Report by Pediatric Acute Lung Injury and Sepsis Investigators and Pediatric Blood and Marrow Transplantation Consortium Joint Working Committees: Supportive Care Guidelines for Management of Veno-Occlusive Disease in Children and Adolescents, Part 1: Focus on Investigations, Prophylaxis, and Specific Treatment. Biol Blood Marrow Transplant. 2017;23(11):1817–25. https://doi.org/10.1016/j.bbmt.2017.07.021 DOI: https://doi.org/10.1016/j.bbmt.2017.07.021
38. Corbacioglu S, Carreras E, Ansari M, Balduzzi A, Cesaro S, Dalle JH, Dignan F, Gibson B, Guengoer T, Gruhn B, Lankester A, Locatelli F, Pagliuca A, Peters C, Richardson PG, Schulz AS, Sedlacek P, Stein J, Sykora KW, Toporski J, Trigoso E, Vetteranta K, Wachowiak J, Wallhult E, Wynn R, Yaniv I, Yesilipek A, Mohty M, Bader P. Diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in pediatric patients: a new classification from the European society for blood and marrow transplantation. Bone Marrow Transplant. 2018;53(2):138–45. https://doi.org/10.1038/bmt.2017.161 DOI: https://doi.org/10.1038/bmt.2017.161
39. Rosenthal J, Sender L, Secola R, Killen R, Millerick M, Murphy L, Cairo MS. Phase II trial of heparin prophylaxis for veno-occlusive disease of the liver in children undergoing bone marrow transplantation. Bone Marrow Transplant. 1996;18(1):185–91.
40. Gloude NJ, Jodele S, Teusink-Cross A, Grimley M, Davies SM, Lane A, Myers KC. Combination of high dose methylprednisolone and defibrotide for veno-occlusive disease in pediatric hematopoietic stem cell transplant recipients. Biol Blood Marrow Transplant. 2018;24(1):91–5. https://doi.org/10.1016/j.bbmt.2017.09.007 DOI: https://doi.org/10.1016/j.bbmt.2017.09.007
41. Parmar V, Lewis M, Shenoy M, Bonney D, Wynn R. Ascitic fluid drainage using a peritoneal dialysis catheter to prevent and treat multi-organ dysfunction in veno-occlusive disease in children undergoing hematopoietic stem cell transplantation. Pediatr Blood Cancer. 2017;64(9):1–4. https://doi.org/10.1002/pbc.26469 DOI: https://doi.org/10.1002/pbc.26469
42. Leimi L, Koski JR, Kilpivaara O, Vettenranta K, Lokki AI, Meri S. Rare variants in complement system genes associate with endothelial damage after pediatric allogeneic hematopoietic stem cell transplantation. Front Immunol. 2023;14:1249958. https://doi.org/10.3389/fimmu.2023.1249958 DOI: https://doi.org/10.3389/fimmu.2023.1249958
43. Elbahlawan L, Qudeimat A, Morrison R, Schaller A. Fluid overload in children following hematopoietic cell transplant: a comprehensive review. J Clin Med. 2024;13(21):6348. https://doi.org/10.3390/jcm13216348 DOI: https://doi.org/10.3390/jcm13216348
44. Pagliuca S, Michonneau D, Sicre de Fontbrune F, Sutra Del Galy A, Xhaard A, Robin M, Peffault de Latour R, Socie G. Allogeneic reactivity-mediated endothelial cell complications after HSCT: a plea for consensual definitions. Blood Adv. 2019;3(15):2424–35. https://doi.org/10.1182/bloodadvances.2019000143 DOI: https://doi.org/10.1182/bloodadvances.2019000143
45. Moreno-Castaño AB, Salas MQ, Palomo M, Martinez-Sanchez J, Rovira M, Fernández-Avilés F, Martínez C, Cid J, Castro P, Escolar G, Carreras E, Diaz-Ricart M. Early vascular endothelial complications after hematopoietic cell transplantation: Role of the endotheliopathy in biomarkers and target therapies development. Front Immunol. 2022;13:1050994. https://doi.org/10.3389/fimmu.2022.1050994 DOI: https://doi.org/10.3389/fimmu.2022.1050994
46. Lucchini G, Willasch AM, Daniel J, Soerensen J, Jarisch A, Bakhtiar S, Rettinger E, Brandt J, Klingebiel T, Bader P. Epidemiology, risk factors, and prognosis of capillary leak syndrome in pediatric recipients of stem cell transplants: a retrospective single-center cohort study. Pediatr Transplant. 2016;20(8):1132–6. https://doi.org/10.1111/petr.12831 DOI: https://doi.org/10.1111/petr.12831
47. Ilan U, Brivio E, Algeri M, Balduzzi A, Gonzalez-Vincent M, Locatelli F, Zwaan CM, Baruchel A, Lindemans C, Bautista F. The development of new agents for post-hematopoietic stem cell transplantation noninfectious complications in children. J Clin Med. 2023;12(6):2149. https://doi.org/10.3390/jcm12062149 DOI: https://doi.org/10.3390/jcm12062149
48. Maqbool S, Nadeem M, Shahroz A, Naimat K, Khan I, Tahir H, Rehman A, Anwer F, Iftikhar R, Lee KY. Engraftment syndrome following Hematopoietic stem cell transplantation: a systematic approach toward diagnosis and management. Med Oncol. 2022;40(1):36. https://doi.org/10.1007/s12032-022-01894-7 DOI: https://doi.org/10.1007/s12032-022-01894-7
49. Pramanik R, Kancharla H, Bakhshi S, Sharma A, Gogia A, Malik P, Sahoo RK, Batra A, Thulkar S, Kumar L. Engraftment syndrome: a retrospective analysis of the experience at a tertiary care institute. Clin Hematol Int. 2019;1(2):114–9. https://doi.org/10.2991/chi.d.190504.001 DOI: https://doi.org/10.2991/chi.d.190504.001
50. Atca A, Erok B, Aydoğdu, S. Neuroimaging findings of posterior reversible encephalopathy syndrome (PRES) following haematopoietic stem cell transplantation in paediatric recipients. BMC Pediatr. 2021;21(1):445. https://doi.org/10.1186/s12887-021-02890-y DOI: https://doi.org/10.1186/s12887-021-02890-y
51. Chen Q, Zhao X, Fu HX, Chen YH, Zhang YY, Wang JZ, Wang Y, Wang FR, Mo XD, Han W, Chen H, Chang YJ, Xu LP, Liu KY, Huang XJ, Zhang XH. Posterior reversible encephalopathy syndrome (PRES) after haploidentical haematopoietic stem cell transplantation: incidence, risk factors and outcomes. Bone Marrow Transplant. 2020;55(10):2035–42. https://doi.org/10.1038/s41409-020-0894-5 DOI: https://doi.org/10.1038/s41409-020-0894-5
52. Gaziev J, Marziali S, Paciaroni K, Isgrò A, Di Giuliano F, Rossi G, Marziali M, De Angelis G, Alfieri C, Ribersani M, Andreani M, Palmieri MG, Placidi F, Romigi A, Izzi F, Floris R, Mercuri NB. Posterior reversible encephalopathy syndrome after hematopoietic cell transplantation in children with hemoglobinopathies. Biol Blood Marrow Transplant. 2017;23(9):1531–40. https://doi.org/10.1016/j.bbmt.2017.05.033 DOI: https://doi.org/10.1016/j.bbmt.2017.05.033
53. Behfar M, Babaei M, Radmard AR, Kooraki S, Farajifard H, Naji P, Taebi S, Hamidieh AA. Posterior reversible encephalopathy syndrome after allogeneic stem cell transplantation in pediatric patients with Fanconi anemia, a prospective study. Biol Blood Marrow Transplant. 2020;26(12):e316–21. https://doi.org/10.1016/j.bbmt.2020.08.021 DOI: https://doi.org/10.1016/j.bbmt.2020.08.021
54. Ito Y, Toyama K, Honda A, Nakazaki K, Arai S, Kurokawa M. Posterior reversible encephalopathy syndrome concurrent with human herpesvirus-6B encephalitis after allogeneic hematopoietic stem cell transplantation. J Infect Chemother. 2020;26(2):265–8. https://doi.org/10.1016/j.jiac.2019.07.016 DOI: https://doi.org/10.1016/j.jiac.2019.07.016
55. Hammerstrom A, Howell J, Gulbis A, Rondon G, Champlin R, Popat U. Tacrolimus‐associated posterior reversible encephalopathy syndrome in hematopoietic allogeneic stem cell transplantation. Am J Hematol. 2013;88(4):301–5. https://doi.org/10.1002/ajh.23402 DOI: https://doi.org/10.1002/ajh.23402
56. Schmidt V, Prell T, Treschl A, Klink A, Hochhaus A, Sayer H. Clinical management of posterior reversible encephalopathy syndrome after allogeneic hematopoietic stem cell transplantation: a case series and review of the literature. Acta Haematologica. 2016;135(1):1–10. https://doi.org/10.1159/000430489 DOI: https://doi.org/10.1159/000430489
57. Zhang Z, Wang C, Peters SG, Hogan WJ, Hashmi SK, Litzow MR, Patnaik MS, Niven AS, Yadav H. Epidemiology, risk factors, and outcomes of diffuse alveolar hemorrhage after hematopoietic stem cell transplantation. Chest. 2021;159(6):2325–33. https://doi.org/10.1016/j.chest.2021.01.008 DOI: https://doi.org/10.1016/j.chest.2021.01.008
58. Lynch Y, Vande Vusse LK. Diffuse alveolar hemorrhage in hematopoietic cell transplantation. J Intensive Care Med. 2024;39(11):1055-70. https://doi.org/10.1177/08850666231207331 DOI: https://doi.org/10.1177/08850666231207331
59. Wu J, Fu HX, He Y, Mo XD, Liu X, Cai X, Gui RY, Liu HX, Yan CH, Chen YH, Chang YJ, Xu LP, Liu KY, Huang XJ, Zhang XH. Risk factors and outcomes of diffuse alveolar haemorrhage after allogeneic haematopoietic stem cell transplantation. Bone Marrow Transplant. 2021;56(9):2097–107. https://doi.org/10.1038/s41409-021-01293-y DOI: https://doi.org/10.1038/s41409-021-01293-y
60. Kapadia M, Shapiro TW. Pulmonary complications associated with HSCT. In: Brown V, editor. Hematopoietic stem cell transplantation for the pediatric hematologist/oncologist. Cham: Springer; 2018. DOI: https://doi.org/10.1007/978-3-319-63146-2_21
61. Yanik GA, Grupp SA, Pulsipher MA, Levine JE, Schultz KR, Wall DA, Langholz B, Dvorak CC, Alangaden K, Goyal RK, White ES, Collura JM, Skeens MA, Eid S, Pierce EM, Cooke KR. TNF-receptor inhibitor therapy for the treatment of children with idiopathic pneumonia syndrome. A joint Pediatric Blood and Marrow Transplant Consortium and Children’s Oncology Group Study (ASCT0521). Biol Blood Marrow Transplant. 2015;21(1):67–73. https://doi.org/10.1016/j.bbmt.2014.09.019 DOI: https://doi.org/10.1016/j.bbmt.2014.09.019
62. Astashchanka A, Ryan J, Lin E, Nokes B, Jamieson C, Kligerman S, Malhotra A, Mandel J, Joshua J. Pulmonary complications in hematopoietic stem cell transplant recipients: a clinician primer. J Clin Med. 2021;10(15):3227. https://doi.org/10.3390/jcm10153227 DOI: https://doi.org/10.3390/jcm10153227
63. Wenger DS, Triplette M, Crothers K, Cheng GS, Hill JA, Milano F, Shahrir S, Schoch G, Vande Vusse LK. Incidence, risk factors, and outcomes of idiopathic pneumonia syndrome after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2020;26(2):413–20. https://doi.org/10.1016/j.bbmt.2019.09.034 DOI: https://doi.org/10.1016/j.bbmt.2019.09.034
64. Jethava Y, Jagasia M, Mohty M, Savani BN. Engraftment and graft failure. In: Abutalib SA, Hari P, editors. Clinical manual of blood and bone marrow transplantation. Wiley; 2017. p. 297–303. https://doi.org/10.1002/9781119095491.ch34 DOI: https://doi.org/10.1002/9781119095491.ch34
65. Ozdemir ZN, Bozdag SC. Graft failure after allogeneic hematopoietic stem cell transplantation. Transfus Apher Sci. 2018;57(2):163–7. https://doi.org/10.1016/j.transci.2018.04.014 DOI: https://doi.org/10.1016/j.transci.2018.04.014
66. Bittencourt H, Rocha V, Filion A, Ionescu I, Herr AL, Garnier F, Ades L, Esperou H, Devergie A, Ribaud P, Socie G, Gluckman E. Granulocyte colony-stimulating factor for poor graft function after allogeneic stem cell transplantation: 3 days of G-CSF identifies long-term responders. Bone Marrow Transpl. 2005;36(5):431–5. https://doi.org/10.1038/sj.bmt.1705072 DOI: https://doi.org/10.1038/sj.bmt.1705072
67. Jaspers A, Baron F, Willems E, Seidel L, Hafraoui K, Vanstraelen G, Bonnet C, Beguin Y. Erythropoietin therapy after allogeneic hematopoietic cell transplantation: a prospective, randomized trial. Blood. 2014;124(1):33–41. https://doi.org/10.1182/blood-2014-01-546333 DOI: https://doi.org/10.1182/blood-2014-01-546333
68. Kanda J, Horwitz ME, Long GD, Gasparetto C, Sullivan KM, Chute JP, Morris A, Hennig T, Li Z, Chao NJ, Rizzieri DA. Outcomes of a 1-day nonmyeloablative salvage regimen for patients with primary graft failure after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2012;47(5):700–5. https://doi.org/10.1038/bmt.2011.158 DOI: https://doi.org/10.1038/bmt.2011.158
69. Kong Y. Poor graft function after allogeneic hematopoietic stem cell transplantation – an old complication with new insights. Semin Hematol. 2019;56(3):215–20. https://doi.org/10.1053/j.seminhematol.2018.08.004 DOI: https://doi.org/10.1053/j.seminhematol.2018.08.004
70. Tanaka T, Inamoto Y, Yamashita T, Fuji S, Okinaka K, Kurosawa S, Kim SW, Tanosaki R, Fukuda T. Eltrombopag for treatment of thrombocytopenia after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transpl. 2016;22(5):919–24. https://doi.org/10.1016/j.bbmt.2016.01.018 DOI: https://doi.org/10.1016/j.bbmt.2016.01.018
71. Tanaka T, Matsubara H, Adachi S, Chang H, Fujino H, Higashi Y, Yasumi T, Kobayashi M, Watanabe K, Takahashi M, Kobayashi Y, Maruya E, Saji H, Nakahata T. Second transplantation from HLA 2-loci mismatched mother for graft failure due to hemophagocytic syndrome after cord blood transplantation. Int J Hematol. 2004;80(5):467–9. https://doi.org/10.1532/ijh97.04063 DOI: https://doi.org/10.1532/IJH97.04063
72. Hasegawa D, Sano K, Kosaka Y, Hayakawa A, Nakamura H. A case of hemophagocytic lymphohistiocytosis with prolonged remission after syngeneic bone marrow transplantation. Bone Marrow Transplant. 1999;24(4):425–7. https://doi.org/10.1038/sj.bmt.1701917 DOI: https://doi.org/10.1038/sj.bmt.1701917
73. Salvador C, Meister B, Larcher H, Crazzolara R, Kropshofer G. Hemophagocytic lymphohistiocytosis after allogeneic bone marrow transplantation during chronic norovirus infection. Hematol Oncol. 2014;32(2):102–6. https://doi.org/10.1002/hon.2052 DOI: https://doi.org/10.1002/hon.2052
74. Sreedharan A, Bowyer S, Wallace CA, Robertson MJ, Schmidt K, Woolfrey AE, Nelson RP Jr. Macrophage activation syndrome and other systemic inflammatory conditions after BMT. Bone Marrow Transplant. 2006;37(7):629–34. https://doi.org/10.1038/sj.bmt.1705305 DOI: https://doi.org/10.1038/sj.bmt.1705305
75. Sandler RD, Carter S, Kaur, H Francis S, Tattersall RS, Snowden JA. Haemophagocytic lymphohistiocytosis (HLH) following allogeneic haematopoietic stem cell transplantation (HSCT) - time to reappraise with modern diagnostic and treatment strategies? Bone Marrow Transplant. 2020;55(2):307–16. https://doi.org/10.1038/s41409-019-0637-7 DOI: https://doi.org/10.1038/s41409-019-0637-7
76. Abe Y, Choi I, Hara K, Matsushima T, Nishimura J, Inaba S, Nawata H, Muta K. Hemophagocytic syndrome: a rare complication of allogeneic nonmyeloablative hematopoietic stem cell transplantation. Bone Marrow Transplant. 2002;29(9):799–801. https://doi.org/10.1038/sj.bmt.1703554 DOI: https://doi.org/10.1038/sj.bmt.1703554
77. Vatsayan A, Pateva I, Cabral L, Dalal J, Abu-Arja R. Post-hematopoietic stem cell transplant hemophagocytic lymphohistiocytosis or an impostor: Case report and review of literature. Pediatr Transplant. 2018;22(4):e13174. https://doi.org/10.1111/petr.13174 DOI: https://doi.org/10.1111/petr.13174
78. ColiŢă A, ColiŢă A, Dobrea CM, Tănase AD, Şaguna C, Ghimici CG, Manolache RM, Angelescu S, Barbu D, Grădinaru F, Lupu AR. Hemophagocytic lymphohistiocytosis: a rare complication of autologous stem cell transplantation. Rom J Morphol Embryol. 2016;57(2):551–7.
79. Sandler RD, Tattersall RS, Schoemans H, Greco R, Badoglio M, Labopin M, Alexander T, Kirgizov K, Rovira M, Saif M, Saccardi R, Delgado J, Peric Z, Koenecke C, Penack O, Basak G, Snowden JA. Diagnosis and management of secondary HLH/MAS following HSCT and CAR-T cell therapy in adults; a review of the literature and a survey of practice within EBMT Centres on Behalf of the Autoimmune Diseases Working Party (ADWP) and Transplant Complications Working Party (TCWP). Front Immunol. 2020;11:524. https://doi.org/10.3389/fimmu.2020.00524 DOI: https://doi.org/10.3389/fimmu.2020.00524
80. Ravelli A, Minoia F, Davi S, Horne A, Bovis F, Pistorio A, Aricò M, Avcin T, Behrens EM, Benedetti F, Filipovic L, Grom AA, Henter JI, Ilowite NT, Jordan MB, Khubchandani R, Kitoh T, Lehmberg K, Lovell DJ, Miettunen P, Nichols KE, Ozen S, Schmid JP, Ramanan AV, Russo R, Schneider R, Sterba G, Uziel Y, Wallace C, Wouters C, Wulffraat N, Demirkaya E, Brunner HI, Martini A, Ruperto N, Cron RQ, Pediatric Rheumatology International Trials Organisation, Childhood Arthritis and Rheumatology Research Alliance, Pediatric Rheumatology Collaborative Study Group, Histiocyte Society. 2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: a European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Ann Rheum Dis. 2016;75(3):481–9. https://doi.org/10.1136/annrheumdis-2015-208982 DOI: https://doi.org/10.1002/art.39332
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Gustavo Zamperlini, Aline Ferrari Martins, Barbara da Cunha Arantes e Silva, Maite Freire Cardoso, Analiz Marchini Rodrigues, Thábata Cristina Paradas Moreira da Silva, Ana Carolina Ferreira Castro Salum, Adriana Seber, Natalia Borges, Alessandra Araujo Gomes
This work is licensed under a Creative Commons Attribution 4.0 International License.
